A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer



Status:Archived
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:April 2010
End Date:May 2011

Use our guide to learn which trials are right for you!

A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies


Assess whether the combination of ABT-888 with temozolomide (TMZ) has activity in subjects
with metastatic castration resistant prostate cancer (CRPC) as reflected by the
prostate-specific antigen (PSA) response.



We found this trial at
5
sites
Medford, Oregon
?
mi
from
Medford, OR
Click here to add this to my saved trials
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Detroit, Michigan
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Milwaukee, Wisconsin
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials